ATE454155T1 - Verwendung von drospirenon zur behandlung von hypertension - Google Patents
Verwendung von drospirenon zur behandlung von hypertensionInfo
- Publication number
- ATE454155T1 ATE454155T1 AT03769738T AT03769738T ATE454155T1 AT E454155 T1 ATE454155 T1 AT E454155T1 AT 03769738 T AT03769738 T AT 03769738T AT 03769738 T AT03769738 T AT 03769738T AT E454155 T1 ATE454155 T1 AT E454155T1
- Authority
- AT
- Austria
- Prior art keywords
- drospirenone
- women
- treat hypertension
- menopause
- drug agent
- Prior art date
Links
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title abstract 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 2
- 229960004845 drospirenone Drugs 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/287,780 US20040087563A1 (en) | 2002-11-05 | 2002-11-05 | Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins |
| PCT/IB2002/004628 WO2004041288A1 (en) | 2002-11-05 | 2002-11-05 | Hormone replacement therapy with drospirenone |
| PCT/IB2003/004946 WO2004041289A1 (en) | 2002-11-05 | 2003-11-05 | Cardiovascular protection using anti-aldosteronic progestins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454155T1 true ATE454155T1 (de) | 2010-01-15 |
Family
ID=32314003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03769738T ATE454155T1 (de) | 2002-11-05 | 2003-11-05 | Verwendung von drospirenon zur behandlung von hypertension |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1558265B1 (de) |
| JP (1) | JP2006508945A (de) |
| AT (1) | ATE454155T1 (de) |
| AU (1) | AU2003278434A1 (de) |
| DE (1) | DE60330888D1 (de) |
| DK (1) | DK1558265T3 (de) |
| ES (1) | ES2338781T3 (de) |
| PT (1) | PT1558265E (de) |
| WO (1) | WO2004041289A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558393A1 (en) | 2004-03-10 | 2005-09-22 | Schering Aktiengesellschaft | Compositions comprising drospirenone molecularly dispersed |
| MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
| EP1669074B1 (de) | 2004-12-01 | 2010-06-02 | Par Pharmaceuticals, Inc. | Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz |
| US20070275941A1 (en) * | 2006-05-17 | 2007-11-29 | Vladimir Hanes | Salt sensitivity and prevention of hypertension with drospirenone |
| EP2052724A1 (de) | 2007-10-26 | 2009-04-29 | sanofi-aventis | Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7 |
| EP2383279A1 (de) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Herstellungsverfahren für Esterol |
| WO2016203044A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| NZ737945A (en) | 2015-06-18 | 2023-06-30 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| RS57328B1 (sr) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu |
| FR3050113B1 (fr) * | 2016-04-19 | 2019-08-02 | Assistance Publique Hopitaux De Paris | Methode de traitement et de prevention des torsades de pointes |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CR20200486A (es) | 2018-04-19 | 2021-01-27 | Estetra Sprl | Compuestos y sus usos para aliviar los síntomas asociados a la menopausa |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| CN117180214B (zh) * | 2023-10-26 | 2024-07-12 | 杭州和泽坤元药业有限公司 | 一种地屈孕酮片剂组合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| AU1480301A (en) * | 1999-11-09 | 2001-06-06 | Pharmacia Corporation | Methods for treating, inhibiting or preventing pathogenic change resulting from vascular injury with an aldosterone antagonist |
| IL150775A0 (en) * | 2000-01-18 | 2003-02-12 | Schering Ag | Drospirenone for hormone replacement therapy |
| AU1604001A (en) * | 2000-06-13 | 2001-12-24 | Pharmacia Corp | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| WO2002009683A2 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| WO2002017895A2 (en) * | 2000-08-28 | 2002-03-07 | Pharmacia Corporation | Use of an aldosterone receptor antagonist to improve cognitive function |
| DE10100911A1 (de) * | 2001-01-11 | 2002-08-01 | Schering Ag | Verfahren zur Hormonersatztherapie und dessen Darreichungsform |
-
2003
- 2003-11-05 ES ES03769738T patent/ES2338781T3/es not_active Expired - Lifetime
- 2003-11-05 PT PT03769738T patent/PT1558265E/pt unknown
- 2003-11-05 DE DE60330888T patent/DE60330888D1/de not_active Expired - Lifetime
- 2003-11-05 AT AT03769738T patent/ATE454155T1/de active
- 2003-11-05 WO PCT/IB2003/004946 patent/WO2004041289A1/en not_active Ceased
- 2003-11-05 AU AU2003278434A patent/AU2003278434A1/en not_active Abandoned
- 2003-11-05 JP JP2004549480A patent/JP2006508945A/ja active Pending
- 2003-11-05 EP EP03769738A patent/EP1558265B1/de not_active Expired - Lifetime
- 2003-11-05 DK DK03769738.0T patent/DK1558265T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004041289A1 (en) | 2004-05-21 |
| EP1558265A1 (de) | 2005-08-03 |
| EP1558265B1 (de) | 2010-01-06 |
| AU2003278434A1 (en) | 2004-06-07 |
| DE60330888D1 (de) | 2010-02-25 |
| DK1558265T3 (da) | 2010-03-15 |
| JP2006508945A (ja) | 2006-03-16 |
| PT1558265E (pt) | 2010-03-22 |
| ES2338781T3 (es) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60330888D1 (de) | Verwendung von drospirenon zur behandlung von hypertension | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| DE60128540D1 (de) | Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen | |
| DE60315964D1 (de) | Verbesserung der herstellung von endogenen gonadotropin | |
| ATE309802T1 (de) | Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| ATE414556T1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| ATE515253T1 (de) | Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| EA200600076A1 (ru) | Композиции и способы увеличения активности теломеразы | |
| DE60320095D1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| ATE461707T1 (de) | Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug | |
| ATE394097T1 (de) | Verfahren zur verabreichung von buprenorphin zur behandlung von depression | |
| ATE500855T1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| DE60216281D1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
| ATE222101T1 (de) | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden | |
| TW200501934A (en) | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1558265 Country of ref document: EP |